140 related articles for article (PubMed ID: 36173886)
1. Development of MAO-A and 5-HT
Sun X; Li N; Zhong P; Chen L; Sun J
J Med Chem; 2022 Oct; 65(19):13385-13400. PubMed ID: 36173886
[TBL] [Abstract][Full Text] [Related]
2. Effect of quercetin and glucuronide metabolites on the monoamine oxidase-A reaction in mouse brain mitochondria.
Yoshino S; Hara A; Sakakibara H; Kawabata K; Tokumura A; Ishisaka A; Kawai Y; Terao J
Nutrition; 2011; 27(7-8):847-52. PubMed ID: 21371861
[TBL] [Abstract][Full Text] [Related]
3. Exploration of oxadiazole clubbed benzhydrylpiperazine pharmacophoric features as structural feature for antidepressant activity: In vitro, in vivo and in silico analysis.
Kumar Nandi N; Das S; Choudhary D; Saini S; Bhatia R; Chawla P; Kaur R; Kalra S; Rawat R; Eyupoglu V; Kumar B
Bioorg Chem; 2024 Mar; 144():107148. PubMed ID: 38306828
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
5. New Human Monoamine Oxidase A Inhibitors with Potential Anti- Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity.
Evranos-Aksoz B; Ucar G; Tas ST; Aksoz E; Yelekci K; Erikci A; Sara Y; Iskit AB
Comb Chem High Throughput Screen; 2017; 20(6):461-473. PubMed ID: 28474547
[TBL] [Abstract][Full Text] [Related]
6. Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors.
Ulus IH; Maher TJ; Wurtman RJ
Biochem Pharmacol; 2000 Jun; 59(12):1611-21. PubMed ID: 10799660
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Villarinho JG; Fachinetto R; de Vargas Pinheiro F; da Silva Sant'Anna G; Machado P; Dombrowski PA; da Cunha C; de Almeida Cabrini D; Pinto Martins MA; Gauze Bonacorso H; Zanatta N; Antonello Rubin M; Ferreira J
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):31-9. PubMed ID: 22525823
[TBL] [Abstract][Full Text] [Related]
8. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents.
Secci D; Bolasco A; Chimenti P; Carradori S
Curr Med Chem; 2011; 18(33):5114-44. PubMed ID: 22050759
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effects of water extract of Gastrodia elata Blume in rats exposed to unpredictable chronic mild stress via modulation of monoamine regulatory pathways.
Lin YE; Lin SH; Chen WC; Ho CT; Lai YS; Panyod S; Sheen LY
J Ethnopharmacol; 2016 Jul; 187():57-65. PubMed ID: 27109341
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibitors of monoamine oxidase. 2. Arylamide SAR.
Harfenist M; Joyner CT; Mize PD; White HL
J Med Chem; 1994 Jun; 37(13):2085-9. PubMed ID: 8027990
[TBL] [Abstract][Full Text] [Related]
11. [Monoamine oxidase as a target for drug action].
Drozak J; Kozłowski M
Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
[TBL] [Abstract][Full Text] [Related]
12. Antidepressant-like effect of the saponins part of ethanol extract from SHF.
Liang Y; Yang X; Zhang X; Duan H; Jin M; Sun Y; Yuan H; Li J; Qi Y; Qiao W
J Ethnopharmacol; 2016 Sep; 191():307-314. PubMed ID: 27321411
[TBL] [Abstract][Full Text] [Related]
13. New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
Salgin-Goksen U; Telli G; Erikci A; Dedecengiz E; Tel BC; Kaynak FB; Yelekci K; Ucar G; Gokhan-Kelekci N
J Med Chem; 2021 Feb; 64(4):1989-2009. PubMed ID: 33533632
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the monoamine system in antidepressant-like properties of 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester.
Galdino PM; de Oliveira DR; Florentino IF; Fajemiroye JO; Valadares MC; de Moura SS; da Rocha FF; de Lima TC; Costa EA; Menegatti R
Life Sci; 2015 Dec; 143():187-93. PubMed ID: 26569034
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine.
Baker G; Matveychuk D; MacKenzie EM; Holt A; Wang Y; Kar S
Chem Biol Interact; 2019 May; 304():139-147. PubMed ID: 30857888
[TBL] [Abstract][Full Text] [Related]
16. Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish.
Sallinen V; Sundvik M; Reenilä I; Peitsaro N; Khrustalyov D; Anichtchik O; Toleikyte G; Kaslin J; Panula P
J Neurochem; 2009 Apr; 109(2):403-15. PubMed ID: 19222706
[TBL] [Abstract][Full Text] [Related]
17. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
[TBL] [Abstract][Full Text] [Related]
18. History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug.
Yáñez M; Padín JF; Arranz-Tagarro JA; Camiña M; Laguna R
Curr Top Med Chem; 2012; 12(20):2275-82. PubMed ID: 23231399
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic system contribution to the antidepressant-like effect of 3-phenyl-4-(phenylseleno) isoquinoline in mice.
Sampaio TB; Bilheri FN; Zeni GR; Nogueira CW
Behav Brain Res; 2020 May; 386():112602. PubMed ID: 32184159
[TBL] [Abstract][Full Text] [Related]
20. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
